Table of contents

• Ovarian Cancer Screening at a Glance
• What Is Ovarian Cancer Screening?
• Who Is a Good Candidate for Ovarian Cancer Screening?
• How Is Ovarian Cancer Screening Performed?
• Why Visit Korea for Ovarian Cancer Screening?
• Key Information for International Patients
• Which Are the Best Clinics in Korea for Ovarian Cancer Screening?
• Ovarian Cancer Screening From Start to Finish
• Alternatives to Ovarian Cancer Screening
• How Can I Prepare for Ovarian Cancer Screening?
• Aftercare Advice

Considering treatment in Korea? Everything you need to know e.g. — how to avoid scams, visas, interpreters, recovery tips — in our Medical Tourism Master Guide. Plan with confidence in minutes, not weeks!

Last updated: September 2026

Ovarian Cancer Screening at a Glance

• Not routine screening — For asymptomatic people at average ovarian-cancer risk, routine CA-125 blood tests and transvaginal ultrasound are not recommended because large trials found no reduction in ovarian-cancer deaths and false positives can lead to avoidable surgery.
• Best use: risk assessment — The most appropriate starting point is hereditary-risk counseling for people with relevant personal or family histories of ovarian, breast, pancreatic, prostate, colorectal, or endometrial cancer, with BRCA1/BRCA2 and Lynch-syndrome testing when indicated.
• Symptoms need diagnosis — Persistent bloating, pelvic or abdominal pain, early satiety, urinary changes, abnormal bleeding, a known mass, or an abnormal prior test requires diagnostic evaluation rather than a screening package; normal CA-125 or ultrasound results do not rule out cancer.
• What testing may involve — When clinically justified, evaluation can include a CA-125 blood draw and pelvic ultrasound, often transvaginal ultrasound; neither needs anesthesia or sedation, but CA-125 can be elevated by menstruation, pregnancy, endometriosis, fibroids, inflammation, or recent surgery.
• No recovery time — After uncomplicated blood collection and ultrasound, normal eating, bathing, work, exercise, sexual activity, and flying can resume immediately; minor bruising or temporary transvaginal-ultrasound discomfort may occur.
• Plan 2–5 business days — A prearranged consultation and appropriate same-day testing can fit into 1 full business day, but 2–5 business days is preferable for reports and a results review; genetic-test results commonly take longer and require remote follow-up.
• Korea-specific pathway — Ovarian cancer is not part of South Korea’s National Cancer Screening Program; the practical Korea option is hospital-based hereditary-risk or gynecologic-oncology assessment, with English records, imaging files, pathology, and genetic reports sent for review before travel.

What Is Ovarian Cancer Screening?

Ovarian cancer screening is an assessment that uses personal and family history, genetic counseling, and selected tests to evaluate ovarian-cancer risk or investigate concerns. It helps identify inherited cancer risk and directs people with symptoms or abnormal findings toward appropriate diagnostic care rather than false reassurance. It is non-surgical, although follow-up for concerning results can involve further testing or treatment.

Who Is a Good Candidate for Ovarian Cancer Screening?

• Hereditary-risk review — Appropriate for people with a personal or family history of ovarian, fallopian-tube, primary peritoneal, breast, pancreatic, prostate, colorectal, or endometrial cancer, particularly when cancers occurred at younger ages or affect several relatives on either side of the family.
• Known inherited risk — People with a BRCA1, BRCA2, or Lynch-syndrome pathogenic variant need genetics-informed counseling on surveillance limitations, reproductive plans, and risk-reducing options.
• Concerning symptoms or prior findings — Persistent bloating, pelvic or abdominal pain or pressure, early satiety, urinary urgency or frequency, abnormal bleeding, a known adnexal mass, or an abnormal prior CA-125 or scan requires diagnostic assessment, not a screening package.
• Pre-travel review — International patients with prior imaging, pathology, genetic results, or a documented family pedigree can use a consultation to establish whether further testing in Korea is clinically justified.

Routine CA-125 blood testing, transvaginal ultrasound (TVUS), or combined testing is not appropriate for asymptomatic people at average risk. Large randomized trials found no ovarian-cancer mortality benefit, while false-positive results led some patients to avoidable surgery and complications, as summarized by the National Cancer Institute. A normal CA-125 or ultrasound does not exclude cancer when symptoms are new, persistent, or worsening. CA-125 also requires cautious interpretation during menstruation or pregnancy, after recent pelvic or abdominal surgery, and with endometriosis, fibroids, pelvic inflammatory disease, or other inflammation. TVUS should be modified, postponed, or replaced when there is severe vaginal pain, active infection, heavy bleeding, recent pelvic surgery, or vaginal insertion is not acceptable.

How Is Ovarian Cancer Screening Performed?

A responsible ovarian-cancer service separates inherited-risk assessment, diagnostic evaluation, and selected high-risk surveillance. These methods do not form a proven routine screening program for symptom-free, average-risk people.

• Hereditary-risk assessment and germline testing — A clinician reviews a three-generation family history, prior cancers and pathology, ancestry, reproductive history, and earlier genetic results. When indicated, testing can include BRCA1, BRCA2, and broader hereditary-cancer panels that assess mismatch-repair genes associated with Lynch syndrome. Pre-test counseling should address positive, negative, and variant-of-uncertain-significance results, implications for relatives, privacy, and follow-up at home.
• CA-125 blood test — This blood marker can contribute to assessment of a suspicious pelvic mass or monitoring after an ovarian-cancer diagnosis, but it is not a reliable standalone early-detection test. Benign gynecologic and inflammatory conditions can raise CA-125, while ovarian cancer can occur with a normal result.
• Pelvic ultrasound and TVUS — TVUS uses a vaginal probe to view the uterus and ovaries without ionizing radiation; transabdominal ultrasound uses a probe over the abdomen. Ultrasound can identify cysts, enlargement, and masses, but cannot reliably classify every lesion as benign or malignant, and routine ultrasound screening has not reduced ovarian-cancer deaths.
• Serial CA-125 algorithms — The Risk of Ovarian Cancer Algorithm (ROCA) assesses changes across repeated CA-125 results and can trigger ultrasound. In UKCTOCS, neither ROCA-based multimodal screening nor ultrasound-only screening reduced mortality in average-risk women after a median 16.3 years of follow-up, an important evidence limitation.
• HE4 and ROMA for an adnexal mass — HE4 and the ROMA score can assist specialist triage in selected patients who already have an adnexal mass. They are not validated population-screening tests for people without symptoms.

Why Visit Korea for Ovarian Cancer Screening?

Korea does not offer ovarian cancer screening as a routine national program, and that is consistent with current evidence. Its official National Cancer Screening Program covers stomach, liver, lung, colorectal, breast, and cervical cancers, but does not include ovarian cancer. For appropriate patients, the practical value of a Korea visit is access to hospital-based hereditary-risk or gynecologic-cancer assessment rather than a consumer screening package.

• Hereditary gynecologic-cancer pathway — The National Cancer Center's Gynecologic Cancer Center describes a hereditary gynecologic-cancer clinic, supporting counseling and specialist care for families affected by ovarian, breast, colorectal, or endometrial cancer patterns.
• Structured foreign-patient referral — NCC publishes an international-patient referral process that requests an English medical letter, medication information, and, when relevant, pathology materials and imaging files for review before attendance.
• Appropriate specialist escalation — An abnormal marker, complex cyst, or suspicious mass can be redirected to diagnostic imaging and gynecologic-oncology assessment rather than being misrepresented as a simple positive screening result.
• Important limitation — Published referral information does not establish a Korea-wide ovarian-screening protocol or guarantee availability of self-referral, English-language genetic counseling, interpreter support, genetic-test turnaround, or secure overseas result delivery. Confirm these details directly before booking travel.

Key Information for International Patients

• Minimum stay — Allow 1 full business day for a prearranged consultation, risk review, CA-125 collection, and pelvic ultrasound or TVUS when appropriate. Allowing 2–5 business days is preferable for reports and a results consultation.
• When not to plan a short trip — Do not arrange a screening-only visit when persistent symptoms, a known pelvic mass, or an abnormal previous result prompted the appointment. Indeterminate imaging can require MRI, CT, repeat imaging, or gynecologic-oncology assessment.
• Genetic-test timing — Germline test results often take longer than a short Korea visit. Arrange secure delivery, a results appointment, and home-country genetics follow-up before travel.
• Flights and activity — Uncomplicated CA-125 collection and ultrasound permit immediate eating, bathing, ordinary activity, and flying. Travel timing changes only when an invasive diagnostic or surgical procedure is recommended.
• Records to bring — Bring an English medical letter; laboratory reports with units and reference ranges; pelvic-ultrasound, CT, or MRI reports; DICOM image files; operative and pathology reports; all genetic-test results; a three-generation family cancer history; and a medication and allergy list. NCC specifies that medical records for its foreign-patient pathway must be in English.
• Remote follow-up — Leave Korea with written results, imaging reports, DICOM files, a clear urgency assessment, and a follow-up plan. Genetic results also need counseling and a plan for cascade testing of biologic relatives when a pathogenic variant is identified.

Travel note: Keep flights flexible until a clinician has reviewed results when symptoms, a mass, or a significant prior abnormality prompted the visit.

Which Are the Best Clinics in Korea for Ovarian Cancer Screening?

Listed below are some of the best clinics in Korea for ovarian cancer screening.

1. SH Clinic

At SH Clinic, your ovarian cancer screening may include ultrasound alongside cervical screening tests such as a Pap smear and HPV testing, with care provided in a specialized gynecology setting by a board-certified gynecologist.

• URL: SH Clinic Website
• Location: Seocho-gu, Seoul
• Screening approach:
  • The clinic lists ultrasound as part of its cervical and ovarian cancer screening service.
  • Pap smears and HPV testing are also listed for early detection of cervical disease.
• Gynecology care:
  • The clinic provides general gynecological care in addition to screening.
  • Its gynecology services include evaluation and treatment options for urinary incontinence and vaginal health concerns.
• Clinician information: Procedures are stated to be performed directly by an experienced, board-certified gynecologist who has received a commendation from the Minister of Health and Welfare.

2. Cheongdam HIFU Clinic

Cheongdam HIFU Clinic provides one-stop diagnostic and treatment services for ovarian and uterine conditions, so you can discuss assessment of an ovarian concern and potential management options in the same gynecology-focused setting.

• URL: Cheongdam HIFU Clinic Website
• Location: Gangnam-gu, Seoul
• Ovarian-condition care:
  • The clinic offers laparoscopic surgery for conditions including ovarian cysts.
  • An ovarian cyst sclerotherapy service is listed as a non-surgical option intended to shrink cysts.
• Treatment options if a condition is identified:
  • Laparoscopic surgery uses small incisions and camera-guided instruments for gynecologic treatment.
  • Da Vinci robotic surgery is listed for complex gynecologic procedures, including hysterectomy or myomectomy.
  • The clinic also offers HIFU for uterine fibroids and adenomyosis.

3. Daegu Spring Women's Clinic

Daegu Spring Women's Clinic offers a women’s health screening center with basic and detailed check-up options, which may be useful when you want a broader gynecologic health assessment alongside discussion of ovarian cancer screening needs.

• URL: Daegu Spring Women's Clinic Website
• Location: Jung-gu, Daegu
• Screening services:
  • The clinic lists basic and detailed women’s health check-ups.
  • Cervical cancer screening, including Pap smears and HPV tests, is available.
  • Menopause-focused and wedding health screening options are also listed.
• General gynecology support:
  • Care is listed for menstrual disorders, abnormal uterine bleeding, vaginitis, cystitis, menopausal changes, and Bartholin’s cysts.
  • Pregnancy management and contraceptive services are available.

Ovarian Cancer Screening From Start to Finish

1. First contact and record review — Send an English symptom history, menopausal status, family pedigree, prior genetic reports, CA-125 trends, imaging, pathology, medication list, and allergies. Ask whether the appointment is for hereditary-risk assessment, diagnostic evaluation, or individualized high-risk surveillance.
2. Virtual or English-language coordination — Confirm whether the hospital can review records before travel, provide English communication or an interpreter, accept self-referral, and arrange genetic counseling if indicated. Obtain written confirmation of required records, test timing, and report delivery.
3. In-person consultation — The clinician reviews family history on maternal and paternal sides, personal cancer history, reproductive history, symptoms, prior findings, and the limitations of CA-125 and ultrasound. A pelvic examination is performed only when clinically indicated; it is not an effective standalone ovarian-cancer screening test, according to the USPSTF.
4. Risk-stratified testing — When clinically appropriate, blood is drawn for CA-125 and pelvic imaging is arranged. TVUS uses a vaginal probe; transabdominal pelvic ultrasound uses an abdominal probe. Neither test requires anesthesia or sedation, and the visit normally permits discharge immediately afterward.
5. Genetic counseling and sample collection — When personal or family history supports testing, counseling should occur before germline testing. The discussion covers what BRCA1/BRCA2 or Lynch-related results mean, uncertain variants, privacy, implications for relatives, and how results will be handled after departure.
6. Integrated results review — The clinician interprets symptoms, examination findings, CA-125, ultrasound, and inherited-risk factors together. An elevated CA-125 does not diagnose cancer, and a normal result does not rule it out.
7. Diagnostic escalation when needed — A complex or indeterminate mass, concerning symptoms, or discordant findings can lead to expert ultrasound review, repeat imaging, MRI or CT, selected additional laboratory testing, or gynecologic-oncology referral. HE4 or ROMA may be used for mass triage, not as routine screening.
8. Discharge and overseas follow-up — After ordinary blood collection and ultrasound, resume normal activities immediately. Before departure, obtain written recommendations and records, then arrange home-country gynecology, hereditary-cancer, or gynecologic-oncology follow-up; schedule a remote review for pending genetic results.

Alternatives to Ovarian Cancer Screening

For average-risk people without symptoms, avoiding routine CA-125 and TVUS testing is the evidence-based alternative because screening harms outweigh unproven benefits. For inherited high risk, the key tradeoff is between surveillance with uncertain survival benefit and risk-reducing surgery, which has lasting fertility and menopause consequences.

No Routine Screening

• Best suited to — Asymptomatic, average-risk people seeking reassurance from a CA-125 or ultrasound.
• Tradeoff — Avoids false-positive findings, unnecessary repeat tests, and surgery. Seek prompt clinical assessment instead when persistent symptoms develop.

Genetic Counseling and Germline Testing

• Best suited to — People with a relevant personal or family cancer pattern, or known hereditary cancer in a relative.
• Tradeoff — Identifies inherited risk and informs relatives and prevention decisions, but results can be uncertain and require expert interpretation rather than a simple positive-or-negative response.

Diagnostic Evaluation

• Best suited to — People with symptoms, an adnexal mass, abnormal imaging, or an abnormal prior result.
• Tradeoff — Targeted imaging and specialist evaluation address an active clinical concern; this is not screening and can require more time in Korea or urgent care at home.

Risk-Reducing Salpingo-Oophorectomy

• Best suited to — Selected people with high-risk pathogenic variants after genetics and gynecologic-oncology counseling.
• Tradeoff — Removal of both fallopian tubes and ovaries reduces ovarian-cancer risk, but causes permanent infertility and, before natural menopause, surgical menopause. It does not eliminate the residual risk of primary peritoneal cancer; NCI outlines the role of preventive surgery for BRCA-related risk.
• Related procedure — Hysterectomy is not equivalent to risk-reducing salpingo-oophorectomy because hysterectomy alone does not remove both ovaries and fallopian tubes.

Opportunistic Salpingectomy

• Best suited to — Appropriate patients already undergoing another medically indicated pelvic operation.
• Tradeoff — Removing the fallopian tubes can be discussed in that surgical setting, but it does not replace individualized management for a BRCA1/BRCA2 or Lynch-syndrome pathogenic variant.

How Can I Prepare for Ovarian Cancer Screening?

• Send records early — Provide family history, prior imaging and DICOM files, pathology, genetic reports, CA-125 trends, and an English medical letter before travel. This determines whether a short risk-assessment visit is appropriate or diagnostic care is needed.
• Disclose clinical details — Report all prescribed medicines, over-the-counter products, supplements, allergies, menstruation dates, pregnancy possibility, recent delivery, and recent pelvic or abdominal surgery. These factors can alter CA-125 interpretation or the timing and acceptability of TVUS.
• Do not stop prescribed medicines independently — Ordinary CA-125 collection and ultrasound do not normally require stopping anticoagulants, antiplatelets, hormones, fertility medicines, or other prescriptions. Follow the treating doctor's instructions if an invasive test or surgery becomes necessary.
• Confirm fasting and bladder instructions — CA-125 alone normally does not require fasting, but other blood work can. TVUS often requires an empty bladder, while transabdominal pelvic ultrasound can require a comfortably full bladder; verify the booked examination in advance.
• Plan menstrual-cycle timing realistically — Do not conceal menstruation or pregnancy. The clinic can decide whether to proceed, reschedule, or interpret CA-125 with extra caution.
• Book flexible logistics — No escort, overnight stay, or special transport is normally needed after blood collection and ultrasound. Stay near the hospital and avoid departing before results review when an existing mass, symptoms, or abnormal prior test is under assessment.

Travel note: A broad health-check visit, including a premarital checkup, is not a substitute for hereditary-cancer counseling or diagnostic evaluation of ovarian-cancer symptoms.

Confirm the treating clinic's specific testing, fasting, bladder, language-support, records, and travel requirements before departure; individualized instructions take precedence over general guidance.

Aftercare Advice

Routine CA-125 collection and pelvic ultrasound require no recovery period, but the meaning of the result—not the physical test—needs careful follow-up.

• Resume normal activity — Eat, bathe, work, exercise, have sexual activity, and fly as usual after uncomplicated blood collection or ultrasound. Mild blood-draw bruising and temporary TVUS or pelvic-examination discomfort can occur.
• Review results in context — Do not treat a normal CA-125 or ultrasound as proof that cancer is absent, and do not interpret an elevated CA-125 as a diagnosis. Review findings alongside symptoms, menstrual or pregnancy status, family history, and imaging.
• Act on persistent symptoms — Seek prompt medical assessment for worsening or persistent abdominal or pelvic pain, bloating, early satiety, urinary changes, fever, fainting, severe pain, a new mass, or abnormal vaginal bleeding.
• Secure your records — Obtain laboratory results with reference ranges, formal imaging reports, DICOM image files, and a written follow-up recommendation before leaving Korea. Send these promptly to the clinician coordinating care at home.
• Complete genetics follow-up — Arrange counseling when germline results return. A pathogenic result can affect risk-management choices and testing recommendations for biologic relatives; a variant of uncertain significance should not by itself trigger preventive surgery.

Follow the treating doctor's individualized instructions, especially if MRI, CT, biopsy, surgery, or gynecologic-oncology referral is recommended, and contact the clinic promptly when something appears wrong.